Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)
Status:
Not yet recruiting
Trial end date:
2030-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of neoadjuvant immunoradiotherapy
(NIRT) prior to surgery for the treatment of stage III and IVA HPV- HNSCC.
Phase:
Phase 2
Details
Lead Sponsor:
Providence Health & Services
Collaborator:
Providence Cancer Center, Earle A. Chiles Research Institute